Czy tylko inhibitory konwertazy i sartany hamują układ renina-angiotensyna? Artykuł przeglądowy

##plugins.themes.bootstrap3.article.main##

Jacek Lewandowski
Piotr Jędrusik

Abstrakt

Wiele dowodów wskazuje na udział układu renina-angiotensyna w patogenezie chorób układu sercowo-naczyniowego. Oprócz enzymu konwertującego i angiotensyn I i II poznano jego nowe elementy: enzym konwertujący 2, angiotensynę 1-7 czy aminopeptydazę A. W ciągu ostatnich lat wprowadzono do leczenia nowe leki hamujące układ renina-angiotensyna. Należy wymienić spośród nich: eplerenon – antagonistę aldosteronu, i aliskiren – bezpośredni inhibitor reniny. Obecnie badane są nowe substancje mogące na różnych etapach hamować aktywność tego układu.

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.themes.bootstrap3.article.details##

Jak cytować
Lewandowski , J., & Jędrusik , P. (2009). Czy tylko inhibitory konwertazy i sartany hamują układ renina-angiotensyna? . Kardiologia W Praktyce, 3(4), 163-168. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1648
Dział
Artykuły

Bibliografia

1. The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. NEJM 2008, 358: 1547-1559.
2. Rump L.Ch.: Secondary rise of albuminuria under AT1-receptor blockade – what is the potential role of aldosterone escape? Nephrol. Dial. Transplant. 2007, 22: 5.
3. Albert N.M., Yancy C.W., Liang L. et al.: Use of aldosterone antagonists in heart failure. JAMA 2009, 302: 1658-1665.
4. Dzau V.J.: Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988, 77: 1-3.
5. Dzau V.J., Sasamura H., Hein L.: Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J. Hypertens. 1993, 11(suppl.): S13-18.
6. Timmermans P.B., Smith R.D.: Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur. Heart J. 1994, 15(suppl D): 79-87. 7. Weir M.R., Dzau V.J.: The Renin-Angiotensin-Aldosterone System: A Specific Target for Hypertension Management AJH 1999, 12: 205S-213S.
7. Campbell D.J.: Critical review of prorenin and (pro)renin receptor research. Hypertension 2008 [online: DOI: 10.1161/HYPERTENSIONAHA.108.110924].
8. Reudelhuber T.L.: A place in our hearts for the lowly angiotensin 1-7 peptide? Hypertension 2006, 47: 811-815.
9. Chappell M.C.: Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin- (1-7)-Mas receptor axis: more than regulation of blood pressure? Hypertension 2007, 50: 596-599.
10. Diez-Freire C., Vazquez J., Correa de Adjounian M.F. et al.: ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol. Genomics. 2006, 27: 12-19.
11. Hernandez Prada J., Ferreira A.J., Katovich M.J.: Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive Agents. Hypertension. 2008, 51: 1312-1317.
12. Benter I.F., Yousif M.H.M., Cojocel C. et al.: Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2007, 292: H666-H672.
13. Ferreira A.J., Raizada M.K.: Aminopeptidase A Could It Be a Novel Target for Neurogenic Hypertension? Hypertension 2008, 51: 1273-1274.
14. Bodineau L., Frugie`re A., Marc Y., et al.: Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension 2008; 51: 1318-1325.
15. Weinberger M.H., Roniker B., Krause S.L., Weiss R.J.: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. 2002, 15: 709-716.
16. Epstein M., Alexander J.C., Roniker B.: Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA), in patients with mild to moderate hypertension. Hypertension 1999, 33: 1075.
17. Pitt B., Reichek N., Metscher B. et al.: Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy for essential hypertension and left ventricular hypertrophy: The 4E Study. Circulation 2003, 108: 1831-1838.
18. Pitt B., Remme W., Zannad F. et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348: 1309-1321.
19. Wood J.M., Cumin F., Maibaum J.: Pharmacology of renin inhibitors and their application to the treatment of hypertension. Pharmacol. Ther. 1994, 61: 325-344.
20. Rajagopalan S., Duquaine D., King S. et al.: Mineralocorticoid Receptor Antagonism in Experimental Atherosclerosis. Circulation 2002, 105: 2212-2216.
21. Brown M.J.: Aliskiren. Circulation 2008, 118: 773-784.
22. Gradman A.H., Kad R.: Renin Inhibition in Hypertension. JACC 2008, 51(5): 519-28.
23. Andersen K., Weinberger M.H., Egan B. et al.: Aliskiren-based therapy lowers blood pressure more effectively than ramipril-based therapy in patients with hypertension: a 6-month, randomized, double blind trial. J. Am. Coll. Cardiol. 2007, 49 (Suppl. A): A371.
24. Stanton A., Jensen C., Nussberger J., O’Brien E.: Blood pressure lowering in essential hypertension with oral renin inhibitor, aliskiren. Hypertension 2003, 42: 1137-1143.
25. Oparil S., Yarows S.A., Patel S. et al.: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized double-blind trial. Lancet 2007, 370: 221-9.
26. Villamil A., Chrysant S.G., Calhoun D. et al.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens. 2007, 25: 217-26.
27. Uresin Y., Taylor A.A., Kilo C. et al.: Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J. Renin Angiotensin Aldosterone Syst. 2007, 8: 190-198.
28. McMurray J.J.V., Pitt B., Latini R. et al.: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail. 2008, 1: 17-24.
29. Parving H.-H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 2008, 358: 2433–2446.
30. Solomon S., Appelbaum E., Manning W.J. et al.: The Aliskiren Left Ventricular Assessment of Hypertrophy (ALLAY) Trial. [online: http:// www.medicalnewstoday. com/ articles/102328.php] .
31. Reudelhuber T.L.: A Place in Our Hearts for the Lowly Angiotensin 1-7 Peptide? Hypertension 2006, 47: 811-815.